Podcasts about GSK

The crimes continue in Southern California, with the murders of Manuela Witthuhn and Janelle Cruz. Paul Holes explains how the offender's violence evolved, how patterns emerged across cases, and how investigators eventually linked the East Area Rapist attacks in Northern California to the Original Night Stalker homicides in the south. For a moment, Paul believes the case may finally be solved. Instead, the investigation enters another long silence. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠antonfloquet.com⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

After the East Area Rapist disappears from Northern California, an attack with a similar MO happens hundreds of miles away in Goleta. At the time, investigators had no reason to connect it to the Sacramento series. Paul Holes helps us understand the shift into Southern California, the jurisdictional gaps, and the violence of the Lyman and Charlene Smith case. Years later, evidence from this phase will become critical to identifying the Golden State Killer. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠antonfloquet.com⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

After an avalanche of earnings updates, we turn to our annual Income Majors special report and dive into two prominent FTSE 100 dividend stocks. First up is insurer Legal & General; pressure has been mounting on the company as it grapples with a more competitive pensions market. Christopher Akers explains the CEO's buyback plan, its yield and what it means for investors.We then move to GSK, once known as GlaxoSmithKline, which faces a tricky balancing act between dividends and developing new drugs. The pharma giant has been spending heavily on R&D – a staggering £18bn this year alone to build its oncology pipeline. Julian Hofmann has the details.Finally, we cast our ears to Hill & Smith's growth across the pond. The steel products company now generates two-thirds of its revenue from the US and has even switched its currency from sterling to dollars. Michael Fahy discusses what's going on at the growing business.Timestamps: 00:00 Intro03:22 Legal & General10:42 GSK18:57 Hill & Smith Listen to more podcasts from Investors' Chronicle on Apple, Spotify and YouTubeInvestors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times. Hosted on Acast. See acast.com/privacy for more information.

The S&P 500 is approaching another record high after a few weeks, powered in part by record-breaking options activity and a recovery from July's brief selloff. We will dig into whether the fundamental and technical picture supports this rally or if investors are getting ahead of themselves.Today's Stocks & Topics: GSK plc (GSK), Market Wrap, Stop Orders, S&P Global Inc. (SPGI), “Refine, Baby, Refine”, iShares MSCI Global Gold Miners ETF (RING), S&P 500 Near Record Highs: Is the Stock Market Rally Sustainable in 2026?, The Greenbrier Companies, Inc. (GBX), WisdomTree US Value Fund of Benef Interest (WTV), Vanguard Dividend Appreciation Index Fund Admiral Shares (VDADX).Our Sponsors:* Check out Anthropic and use my code Claude.ai/invest for a great deal: https://www.anthropic.com* Check out Quince and use my code quince.com/INVEST for a great deal: https://www.quince.comAdvertising Inquiries: https://redcircle.com/brands

Como os gargalos no acesso a terapias metabólicas, os alertas regulatórios sobre insumos médicos e o uso da inteligência artificial no desenvolvimento de fármacos transformam a medicina? Neste episódio do Afya News, analisamos as discussões do Congresso Internacional de Obesidade 2026, que destacam a necessidade de integrar políticas públicas de prevenção, atenção primária e farmacoterapia para superar as barreiras de custo e acesso. Discutimos também a medida da Anvisa que suspendeu a comercialização e uso de dispositivos médicos e insumos hospitalares irregulares. Por fim, apresentamos no Radar o investimento da GSK em inteligência artificial para mapear novos alvos terapêuticos em doenças como fibrose e osteoartrite. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/11-08-2026Conteúdo 100% validado por equipe médica.Médico Responsável: Dr. Guilherme Rodrigues — CRM-RJ 1049461.

Today's guest is Clare Hickie, Chief Technology Officer, EMEA at Workday. Founded in 2005, Workday is a leading enterprise software company that provides cloud-based solutions for human capital management (HCM), finance, planning and AI-powered business operations. Workday serves more than 11,500 organizations worldwide, including over 65% of the Fortune 500. Workday helps businesses streamline operations, improve workforce management and make faster, data-driven decisions through its secure, intelligent cloud platform.In her role with Workday, Clare partners with senior business and technology leaders to help organizations transform how they manage people, finance and AI. With more than 30 years of experience in enterprise technology, Clare began her career on the customer side, spending 15 years at GSK before joining Workday in 2018. She is a recognized leader in responsible AI, cloud transformation and enterprise innovation, with a strong focus on building trusted, human-centered AI solutions that deliver measurable business impact.In the episode, Clare discusses:0:00 How AI conversations evolved from skepticism to agentic productivity5:51 Co-creating with customers to deliver proven AI outcomes7:19 How Workday's AI agents deliver significant productivity gains9:06 Creating consistent AI experiences built on a unified platform12:46 Responsible AI requires governance, transparency and risk management17: 33 How trust and responsible AI drive lasting customer adoptionTo find out more about all the great work happening at Workday, check out the website www.workday.com

The East Area Rapist did not stop terrorizing victims when he left their homes. Paul Holes walks us through the phone calls, threats, and psychological cruelty inflicted on the victims long after the attacks. This episode explores fear as part of the offender's pattern. Paul also traces the final Northern California attacks and the moment the series abruptly stops in the north before starting up again somewhere else in the state. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

How can content marketing in a tight niche build the audience that launches your book? And how do you decide whether to hand your self-published bestseller to a traditional publisher. Suzanne Smith shares what she learned in four years of going from blog to book deal. In the intro, how to stand out as a writer in the age of AI [Nathan Barry Show; Interview with Nathan Barry]; thoughts on asset maintenance; Goodreads giveaway on Bones of the Deep (Aug 5-20, 2026) This episode is sponsored by Publisher Rocket, which will help you get your book in front of more Amazon readers so you can spend less time marketing and more time writing. I use Publisher Rocket for researching book titles, categories, and keywords — for new books and for updating my backlist. Check it out at www.PublisherRocket.com This show is also supported by my Patrons. Join my Community at Patreon.com/thecreativepenn Suzanne Smith is the founder of The Independent Landlord, and the bestselling author of The Good Landlord Handbook. You can listen above or on your favorite podcast app or read the notes and links below. Here are the highlights and the full transcript is below. Show Notes How a free blog in a tight niche built the audience for the book Rewriting the book from scratch when the law changed Why speed made self-publishing the only option Building a paid membership after one audience member asked for it Negotiating a Penguin Random House deal with no agent Using AI as a business sidekick, with a control room and an engine room You can find Suzanne at TheIndependentLandlord.com. Transcript of the interview with Suzanne Smith Jo: Suzanne Smith is the founder of The Independent Landlord, and the bestselling author of The Good Landlord Handbook. So welcome to the show, Suzanne. Suzanne: Thank you. Jo: Oh, there's so much to talk about today. But first up— Tell us a bit more about you and your background, and how you got into property and writing after a legal career. Suzanne: Well, I've always loved reading books. In fact, I recently did a French literature degree as a mature student. Being an author was never in the game plan at all. It's not something that I even thought about. I was brought up in New Zealand, so shout out to all the Kiwis and those across the pond in Australia. The thing about it is, Jo, you've lived there yourself. Kiwis are independent, self-reliant and have this great sense of fair play. So that was a very formative experience for me. We moved back to England when I was 16, and I have become thoroughly anglicised since then, but a Kiwi at heart. I always wanted to become a lawyer. New Zealand in some ways on television is quite American, and there was this American programme called The Paper Chase. It was about all of these students at Harvard studying law, and the professor said, “You come here with a skull full of mush and you leave thinking like a lawyer.” I thought, “Oh, I like the sound of that.” I didn't really know what a lawyer was, but everyone seemed to be very happy that I wanted to become one, and then that was it. Jo: So you went into law, and then how did you get into property? Suzanne: So I worked for 25 years as a solicitor. That's like an attorney if you're American. Started off in a law firm, and then I went into pharmaceuticals and I worked for big companies like what is now GSK, GlaxoSmithKline, and small companies as well. When I started out, it was before the internet, before Google. When you're in house, you're very much a generalist. You do a bit of everything. So you help companies grow their business. You're not business prevention, but you're still bound by the code of conduct for solicitors. You've got this role of keeping the company on the right side of the law. Then I had twins, who were born about five years after I became a lawyer, and I decided to work part-time for a while and did an MBA when they were little, part-time through the Open University. I know Jonathan is doing one at the moment. Jo: Yes. He's finished, so that's exciting. Suzanne: That was transformational for me, because I had probably been thinking a bit too much as a lawyer, and it helped me to broaden my view of the world and understand all sorts of things. Sso I continued going up the greasy pole, and then for my last job, in 2015, I joined a biotech company in Cambridge, England, as general counsel and company secretary. It was a long way from home, about two, three hours' drive from home. So I decided to buy a flat, an apartment, and to stay there in the week. I thought to myself, “Well, when I leave this company, I can let it out as a buy-to-let,” but actually as a landlord. So I stayed there for five years, and then when I left, I let out the property. The reason why I decided to leave law after 25 years, I had what I call a sliding doors moment, like in the film. I was 50. I was on holiday with my husband, and we'd probably had one too many rum cocktails. And he said to me, “Well, what do you want to be doing with your life? What would you do if you could do anything?” I was thinking, “Well, I've done law. I want to do something else now.” I didn't really know what that was, and I'd always been thinking about studying French properly, and that's when I left. So I decided, 18 months later, I left to do a French degree at King's College London, full-time. I was the only old person there with lots of 18-year-olds. When I did that, I was able to cash in my share options because I was a good leaver. I retired, and so I started buying properties to let out and became a landlord, without really thinking too much about it, and I used letting agents. They were fine to begin with, but I didn't really have a game plan or anything like that. What I realised is that when I tried to research things online, I couldn't really find anything that was terribly helpful. It was either quite general or it was very legal. So after a while… I became a landlord in 2019. I had the idea, why don't I set up a blog? And this is August 2022, so just four years ago. My husband came up with the idea of the name, The Independent Landlord, because it's that Kiwi spirit, being very independent. I thought, “Right, I'm not going to charge anyone for it. It's a hobby. It's not a business. I'm going to pay it forward and help, use my legal training, practical legal approach, and practical common sense, by doing this blog.” Almost exactly four years ago, I sent my first newsletter to 13 people. Jo: Woo-hoo. Suzanne: And I sent one last week to over 18,000. So it's been quite a journey. Jo: Wow, this is so great. I love this. There's so much in there. The turning 50 and then doing a degree. My master's in death is a little different to your French literature, but I like it. So I love this, and buying properties, starting it on the side, not a business at first, and growing the audience, and obviously you've put so much work in. Then you decide to write a book. So talk about that, because an online blog, although I'm sure your articles and everything were super useful, it's very different to write a blog than a book. So talk about your challenges in writing. Why did you decide to do a book in the first place? Suzanne: Again, I was an accidental landlord, is what they call it when you let a property when you didn't intend to buy it as a buy-to-let, which I did with my Cambridge flat. And I became, in many respects, an accidental author. So I was having a conversation with my husband again and I was saying I'd done this lead magnet to get people to sign up to my newsletter, and a big new law was going through Parliament at the time, called the Renters Reform Bill, that was going to completely transform the way landlords operate. I was saying to my husband, “Oh, I need to update my lead magnet, a little ebook, to explain the new law.” He looked at me and said, “Well, why don't you do a proper book? Write a book.” This was on the 29th of September, 2023. The reason why I mention that is that I thought, “Wow, what a great idea,” and my head was bursting. I went onto Google, and guess what I downloaded on the 1st of October? Jo: My blueprint? Suzanne: Exactly. I found you immediately, the Author Blueprint, and I downloaded it. I checked: on the 1st of October, 2023. Then I listened to almost… well, I think I went back several years on your podcast, just trying to understand. I'm like that. When I try and do something, I just try and learn everything that there is to know about it. So I started writing the book, and I guess the first challenge was I write quickly, and I'm used to writing for people who aren't lawyers, being in-house. So I thought I needed to have a structure. The structure was easy in many respects because, a bit of business at the end, and then you can go through a tenancy. I thought it was important to have a narrative thread all the way through it, just to bring it together. This is the literature degree coming in here. I thought that the mission for everything I do, the reason why I started doing this, is to help landlords, but also to help the experience of renting that people have in England. It's very specific for English law. And to help improve the private rented sector. So that's why I originally set up my blog for free, and I wanted, when people went onto Google, they could find something sensible and very detailed from me. My blog posts were… Well, I've now got over 400,000 words on my blog, so it's a substantial piece of work that is out there free of charge. So what I decided to do was to bring this narrative thread, I call it the good landlord ethos, to the book. Then I wrote very quickly, and I had a pretty good draft by April 2024, because we were all thinking that the law was going to change very soon. But then there was an election, and in the end the government changed and the legislation changed completely, so I had to rewrite the book and start again. So I think that my biggest challenge was that my subject matter, the new law, changed. Because I wanted to publish this book that explained to people practically what they have to do, and make it really straightforward, keeping out of politics, because it is a very politically charged area. I wanted to write it so it's a manual, somebody could literally follow it. So I used an editor, and I did write the book twice. I had a beta reader who is another lawyer, and a landlord as well. Then I got to the get-the-damn-thing-done stage. The really tedious bit of all the typos at the end. Jo: Yes, the finishing energy to get it out there. So at that point, obviously you'd found my blueprint, so you were learning about the indie way of doing things. Did you always decide to self-publish? How did you think about publishing? What were your challenges in publishing? Suzanne: It never occurred to me not to self-publish, because the new law came into effect on the 1st of May, 2026. The law and the details that I needed for the book were finalised in January, and I published on Amazon on the 5th of March, so I had to go so quickly. Even though I'd got a lot of it written, the last bit came in January, and so I needed speed. I knew that for landlords to be able to have something that they can use straightaway to help get them ready for it, and then use as a manual afterwards, I had to be first. Jo: Sorry, just on the year. Was it '24? You said '26. You meant May— Suzanne: 2024? No, no, because I actually published it this year. What happened in 2024, I had the first draft ready, but then I had to do another draft because the law changed when the Labour government came in. Jo: Right. Suzanne: The Renters Reform Bill turned into the Renters' Rights Bill. So I had to rewrite the book. So I finished however many drafts at the end of January 2026. Then it went to an editor, et cetera, et cetera, and I managed to get the book ready for a proof, to get the proof printed, towards the end of February. So it was really quick to go from the law being sufficiently finalised for me to write a book in January, and then having it ready in just over a month. There is no way that I could have done that if I'd gone to a traditional publisher. It didn't even occur to me to go, because I didn't want to be going touting around my book and, “Please publish me,” et cetera. It's just not me. I'm the independent landlord, and that moved very easily to being the independent publisher. So I learnt how to do all the publishing. And a huge thanks: I joined your Patreon and I was a very good student. I went through everything systematically and followed your playbook, and used Vellum and BookFunnel and all the other tools. So I decided to go on Amazon as well as have my own Shopify store, which just about killed me. Jo: I was going to say, you are an excellent student. You really like learning, but you also put this into practice, which is why I also wanted to talk to you. You haven't just talked about all this. You've literally done everything. Suzanne: Sometimes it was like my head was going to burst. Luckily, Claude upped his game earlier this year when we got the Opus 4.5. I didn't use AI really until this year. I decided I need to do exercise all the time, and have that as a have-to-do, because my head was spinning all the time with all these different things. So I would go to the gym, go to a spin class, and then I would walk out with my phone on, with the Claude app, and dictate a stream of consciousness into it. “Oh, I need to do this, or what about that? Oh, I just remembered about this. Oh, I've had this idea, blah.” And then said, “Make sense of it for me, Claude.” So it was very much as a thinking partner, because when you're writing your first book, it's bad enough, but when you're learning how to publish… Even, like, when I got the first proof of the book back from BookVault, I realised that all the footnotes—I have 114 footnotes in my book, and that, again, is the recent degree there—and the formatting had gone skew-whiff. Apparently it was an issue with Vellum, and they were really lovely and they sorted it straight out for me. So it shows: always get a proof of the book. They were able to sort that out very quickly, and BookVault were very quick in getting me another proof, because you can shortcut it and just pay to get a very quick delivery. Amazon, on the other hand, was really slow. It took a week. So I actually published earlier on my Shopify store for my members, of my membership, and I gave them a discount. Then I finally got it onto Amazon on the 5th of March. There are all these different skills you're having to learn. The Shopify store I found very hard, and there was all the tax, because I'm VAT registered. So I think I'm still recovering. Jo: You're still recovering. I wouldn't normally recommend a Shopify store for someone with their first book, doing first of everything. But, as you say, you're someone who learns a lot, puts it into practice, and— I think you were pretty determined to do that because you had a community as well, right? Suzanne: Exactly, yes. The big subscriber list. I think that's why the book did so well. So in the first week, because I met you at the Indie Author Lab put on by— Jo: Yes, London Book Fair, yes. Suzanne: Yes, the Alliance of Independent Authors. I met you there, and it was just my first week, and I had 1,000 sales in the first week. That was because of my audience. I'd been going on about the fact that I'm writing this book for two and a half years, because that's how long it took me to do. So I had a wait list for it, and I had a thing on my website, a landing page on my website, saying how good the book was and why it's the best thing for the Renters' Rights Act. Then I went onto Google, and I think I sent you a screenshot of this at the time. I put into Google, “What's the best book for the Renters' Rights Act for landlords in England?” And it came up with me as a featured snippet, and I hadn't even published it at that time. It was just about there. So the blog really helped, because I'd become an authority on the Renters' Rights Act. Even though I'm not a practising solicitor any more, I spent all my time reading the damn thing, and it is a very complicated bit of legislation. Funnily enough, I have ruffled a lot of feathers. People have even said about me behind my back, “What does she know? She's only got four properties.” But I just took no notice. I thought, “I'm going to try and use my legal brain and my understanding of what it's like being a landlord, there with the rubber gloves cleaning an oven when people have moved out, and try and write something that's not trying to sell anything else, and to help people.” And then it got picked up. Jo: Yes. Wait, let's just slow down. Slow down, because we will get onto that in a minute. But let's just come back to that launch. So as we talked about, you've had a blog for five years— Suzanne: It was three and a half by then. Jo: Three and a half years you've been blogging, but hundreds of thousands of words of useful information. So you've essentially done content marketing. You've attracted people. You had a lead magnet. You got them on your email list. You told them that you were writing a book. You got a sort of pre-sales list up. So that's an email list. You've got a blog. Did you do anything else in terms of marketing? Suzanne: I had YouTube, a big YouTube channel. I'd only set it up at the end of 2024, and I'd had half a million views. And again, just very straightforward advice, and without all the scaremongering and politics. I deliberately keep out of it all. A lot of people joined my newsletter as a result of that. Also a year ago, exactly today, I was running a Facebook group, which was a lot of hard work. There were a few thousand people in it, but there are often a lot of people going in there trying to sell things: insurance, eviction specialists and things. And there was also a lot of people just being unpleasant to other people. I was getting fed up with it. It was taking me a lot of time, and I was doing a lot of speaking events and trying to explain what this new law was doing, and wearing myself out. I'm an extrovert, but even I find speaking events absolutely exhausting, because it's like everything gets sucked out of you. It's strange. Then somebody came up to me in July last year and said, “Suzanne, can you set up a membership?” I said, “Well, landlords aren't going to pay for that.” And they said, “Yes, they will. You build it and they will come.” I asked ChatGPT and thought about it. I asked ChatGPT, who I was dating at the time, now exclusively with Claude, but I know Claude has other people in his life. But I'm very much set with Claude Fable at the moment. So I asked ChatGPT, how can I go about setting up a membership? And I mentioned your one and said, “Should I do it on Patreon?” And then he came back with: go for Circle. So I set up a membership on Circle, exactly a year ago. In fact, it's the anniversary of my first member yesterday. hTe rules I had were, no selling. So I don't sell, no affiliate links, no one else can sell anything, and we have to be supportive. No negativity, no politics. So what it's become, it's like the senior common room of the private rented sector, with landlords, lawyers, letting agents. There's a fantastic forum in there. It's not me doing it, it's peer-to-peer. I have twice-monthly live streams where people can ask me questions. I wonder where I got that from. No, I very much modelled it on your Patreon, but on a different platform. I have courses in there as well. So that has really grown. I launched it in July, and by September, October, I'd gone past the VAT threshold, which has complicated everything, but it means my business now is this membership. I really enjoy doing it, and there hasn't been all the negativity that you have in a Facebook group. So I had them as… talk about your thousand fans. There are about 1,500 in the membership, and their support really helped the launch of my book, as well as the wider people who get my free newsletter. Jo: Yes. Suzanne: So it's all different types of content marketing. Jo: Y, but I do love this. And of course, if people are wondering, I joined Patreon back in 2014, I think it might have even been before that, and there weren't too many places back then to run communities. It wasn't even really a community at the time, it was a sort of, almost a “give me a bit of support for the podcast.” So things have changed a lot in terms of communities, and obviously you went with Circle, which is great. Patreon is slightly different now, and some people are using Substack for something similar. So that's just on the platform, but on the business: early on in our conversation you said, “I wasn't going to have a business. It wasn't a business. It was just putting stuff out there, helping other people,” and then your audience asked for this membership. And so now it is a business, right? Suzanne: Yes, it is. Jo: And you've got a book and all of this. So are you happy with the change to a business? Because obviously you have to treat it quite differently. Suzanne: Yes, I am, because I think to begin with, I was just doing it one or two days a week. I was actually studying a master's in French literature part-time, and I then found that I was enjoying the blog more than the master's, so I dumped the master's after the first year. But after getting 88% for one of my dissertations, which interestingly was on the translation of a Simone de Beauvoir book into English, and the publisher who's got that now is Random House, but that's another thing. Anyway, so I decided to give up my master's and double down and work full-time on the blog. People were paying to help me with all the big fees and things, the big tech stack, Buy Me a Coffee. I was doing a little bit of consulting and things. I was working six, seven days a week. I was treating it like a business in terms of quality and my effort, but it wasn't a business in terms of revenue. Then it just all came together, and this person said, “Set up a membership,” and I thought, “That's what I'm going to do. I'm now going to put it on a business setting.” I've got an MBA, I know how to do it, and people thought I planned it, but I didn't. It just happened. So now I do very much treat it as a business, but I still don't advertise. I don't allow people to advertise with me, because I want to be independent. If I recommend something, I want people to believe it's me recommending it, not just because someone's paying me, which can be a big issue in the landlord area. Jo: Oh, in any industry. I get pitched every day with loads of random things that people are like, “Oh, a dollar a click or whatever, if you send this to your list.” And it's like, seriously? Just stop it already. I did just want to add there: somebody asked you, they said, “You should have a community,” and that sparked that idea. I just wanted to acknowledge that my Patreon came from Jim Kukral. Some of you will remember, who've been around a long time. Jim Kukral came on my blog around sort of 2013. Amanda Palmer had just put out a book called The Art of Asking, and I was doing a lot of unpaid work on the podcast at the time, and I was either going to give it up or I had to fund it somehow. Jim said, “You should do a Patreon.” And I was like, “Oh, no, I hate asking for money.” So at the time I just felt, oh, weird. Then I was like, “No, I do all this work,” as you were saying. Now the Patreon has changed so much in terms of what it is, but it is the backbone of my business, too. So I love that you listened to one of your fans who said what they wanted, and I love that I've listened as well. Sometimes we just have to listen to those urges, don't we, to take things on? Suzanne: Yes, absolutely. In some ways I didn't really back myself before. I thought, “No one's going to pay for this.” Then the more you give, the more they want. Jo: Yes. Suzanne: What I've been really working on now is having boundaries, because there were two big kind of mottos that I picked up when I was working in pharmaceuticals. One was from a head of the business. He was Canadian, and he was always saying, “You've got to skate to where the puck is heading.” Jo: That's Wayne Gretzky, is it? Suzanne: Exactly. Yes. He would always say it, and so that's what I've done with my blog and my book. When I write things, I don't pay for any tools. I don't do keyword searches and all that. I just think, I do one blog post per topic, and I'm going to guess what people are going to be searching for soon, and I build up all this content around it. That's why most of my blog pages are top five. I've had no advertising. I haven't asked for any backlinks. I don't do it. People backlink to it because it's useful. So that was the first thing, is skate to where the puck is heading, and that was my approach with the book. I knew people would need this book from around May, and they'll need it forever, because it is so complicated and regulated, the rules for being a landlord in England. So that was the first one. The second thing was: when you take something on, you've got to let something go. One in, one out. I found that I was taking on so many different things, and I've just been cutting back, because I can't be doing all the speaking, I can't be answering people's emails. So I now don't do emails. If people want my advice on something, they ask me in the hub, at the twice-monthly live streams. Sometimes I answer in the forums, but I don't have time. When there are 2.4 million landlords in the UK, and even with our 18,000 on my newsletter, I could spend, and I did, I used to spend all my time replying to emails. So anyway, there are the things. Oh, and there was a third one, which is: attract, don't chase. One of my friends gave me that advice and that's exactly what my approach has been. I just don't chase for anything. I just put the stuff there and then build it and they will come. Jo: Yes, and I think another thing is the power of the niche. It's so clear that what you write about, the people you are aiming at, you have an extremely tight target market. That is both a strength and obviously a weakness, because they're the only people. But as you say, there's more than enough of those people for a community, for the book you have. From my own perspective, that's the same for me, the power of the niche. That's how I have a successful podcast, for example, because of that reason. I think you're like a poster child of what a non-fiction author should do. What I like is that you didn't go, “Oh, where's a niche where I could make money?” and then jump in. You've gone about this in a kind of slightly accidental way, but now you're leaning in and this uses all your skills. So this really is a great example of the power of the niche and then making the most of it. But let's move on to what then happened, and— What happened with the book deal? Suzanne: Wow. So you and I met each other on whatever day that was in March at the Indie Author Lab, and the following day I got an email, via my website on a contact form, from Penguin Random House saying, “We love the book. We love the mission, its values,” all this kind of thing. And I was thinking, “Oh, it's another one of those. Must be an—” Jo: AI spam bot, right? Suzanne: Yes, and I remember I sent you a screenshot of it, and then I checked her out on LinkedIn and thought, “Okay, there is somebody with that name there.” You're always saying, and Orna Ross and everyone are always saying, “Watch out for scams.” And in fact, Penguin Random House even this weekend on Instagram put out something saying, “There are lots of people impersonating us.” So I didn't take it too seriously, and it was something like, “Oh, would you be interested in us publishing your book?” And I thought, and I laughed. It was like, no, this is too good to be true. So I replied and said… Oh, I said, “Well, thank you so much. The Renters' Rights Act…” And so this is like the second week in March. “The Renters' Rights Act comes into effect on the 1st of May. If you want to publish it, you're going to need to get your skates on.” I literally did say that. Then she arranged a meeting with me the next day, on the Friday. I still was very dubious about it, and I had a think about it. What helped me, and I have the little booklet here: at the Author Lab, we did some work at the beginning, and Orna said, “Put your phones away.” And it was like, “What? Put my phone away?” Then we had to do this definition of success, and our passion, and our mission, and our purpose. I wrote down things like, I want to help landlords, and in so doing, help improve the private rented sector. I get pleasure from helping people. I want to improve standards and use my legal and practical skills, et cetera. So I thought, “Okay, what is my purpose of doing this book?” It isn't really to make money, because going with Penguin, you wouldn't do that for financial reasons, because you'd make very little money. So I thought, what is my why? My why is I want as many people to read this book as possible. And I've managed to sell a few thousand copies, but there are 2.4 million landlords, and they all need to understand this book, and the only way that I can get it out there, apart from doing ads, is to get it out in bookstores. So I thought about it, and then said, “Yes, I will do it, because I want to get the book out there.” So it's distribution. It's going to be published on the 6th of August, which is really quick, bearing in mind they contacted me in the middle of March. It's exactly the same book, it's just got different copyright wording and different blurb, different paper. Same cover, because I managed to find a fantastic cover person to do it. So they've kept everything the same. So we negotiated that book. I have no agent. They came to me. It's the attract, don't chase. I just put my lawyer hat on, and because one licence is very much like another one… I did turn down their first offer. Jo: Well done. Good negotiation. Suzanne: My daughter said to me, who's an adult daughter, she said, “But it's Penguin.” And I said, “Well, no, but it doesn't work for me.” So I had a call with them, and then they came up with something that worked for me a bit more. I did have to concede on a few things, like I can't sell it in my Shopify store. But in some ways, that was a blessing in disguise, because it means I don't get any more “Where's my book?” emails. Jo: Yes, exactly. Pros and cons of everything, basically. Suzanne: I have very clear rights to get it back. If I want it back, I can get it back and I don't have to give a reason. They're lovely. They have been really very wonderful. When I went up there a month or so ago, they gave me this book bag, and it's got on it, “I'm published by Penguin,” and I burst into tears. Jo: Aw. That's nice. Suzanne: I don't know, it just seemed like such a big deal. Because up until then I was just being all very lawyerly and task-orientated. Then I thought, “Oh my goodness,” and then it dawned on me. So I'm now in this interim period where I've taken it off Amazon and off my Shopify store, and I feel very maternalistic towards the book because, you know, it took me two and a half years, which is longer than a pregnancy. Obviously it's not a child, but it's like my book child. I've sent it off with a backpack and a drink and some snacks, and I hope that they look after him, my book. The day I took it off Amazon it was still number one. And a big shout-out to Publisher Rocket, by the way. Jo: Yes. Very, very useful for niche publishing. Suzanne: Very. It helped me choose the right niche categories. So it was number one on at least one category, often six, all the way through. I thought, “Well, it's over to them now.” They're very lovely people. They've given me some marketing assets, as they call it, some swanky graphics and things to use. We'll have to see what we do in terms of marketing. I don't mind doing marketing. I'm on LinkedIn quite a bit, and my whole blog is marketing. What I've been doing is updating my blog to include one of these graphics and to mention the book, and I got Claude to help me draft the code so it looked right. So I've been going through all of my blog posts and sending people to Amazon rather than to my Shopify store. It is mixed feelings, because I care about my book. I put a lot of effort, a lot of love, a lot of tears. No, not tears, but I put a lot of effort into it, and it's out of my control now. Jo: Yes, you said it's over to them, but obviously you will still be creating content around this topic, so you'll probably still be the biggest driver of book sales. Suzanne: Yes. Jo: Are they also suggesting, for example, a podcast tour, like pitching for podcasts? Are they going to assign you some PR? Because, also if people don't know, as we are recording this, we have a new prime minister who wants to do various things. You said no politics, but this is obviously a political thing. So you have the potential to go on a lot of different podcasts, media, talking about this, becoming almost a talking head in this kind of area. So are you angling for all that, and is that in your contract, or is it literally just going to be whatever you want to do? Suzanne: That's not in the contract. What's in the contract is very minimal. I think I've already done what I'm supposed to do. They are pitching for me to go on podcasts and things. I'll tell you a really funny coincidence. So we now have a new Prime Minister, Andy Burnham, and when he was Mayor of Greater Manchester, he set up something called the Good Landlord Charter. I actually talk about it in the book, and I quote him in my book saying that good landlords mean people trying to do the right thing, or something like that. And I coincidentally came up with the same name, The Good Landlord Handbook. I'd already had the book title for a long time. So this idea of good and landlord coming together, the adjective good as opposed to criminal or rogue, and the cover being green. I'm wanting to change the narrative so it's the norm to have a good landlord, and to help people become good landlords. Or if they're good landlords, help them to understand the new rules, because the new rules are very complicated. So what I don't get involved in is this right or wrong. Is it right that landlords can't do this or have to do this? Because as an in-house lawyer, it doesn't really matter what I think about the law. GDPR, goodness me. Jo: Oh, dear. Let's not start on GDPR. Suzanne: No, exactly. Because we've just got to suck it up. I liken it to the grief cycle, that people have been going through so much change and you have the anger, the depression— Jo: Denial. Suzanne: Bargaining, the denial, and then you get to acceptance. For some people, the acceptance means they want to stop doing it. If you want to accept it and stay, you need to understand the rules. So I've deliberately just kept very practical and have kept out of all the politics of it. I have, funnily enough, become involved because I'm now seen as an expert on the Renters' Rights Act. I've worked behind the scenes with the government to help, and give comment on government guidance for landlords. I was even invited to a reception to mark the passing of the Renters' Rights Act at Downing Street with the previous prime minister, all whilst staying apolitical. I won't let anyone make me be a mouthpiece for their political view. It's more, we just have to do this if we want to continue doing it. I've been very clear on that. Jo: It's interesting you mention the grief cycle there, and you've also mentioned Claude and ChatGPT. I wonder if you might also just comment on use of AI for authors and for marketing and all this. Also with legal stuff, because for me now, if I'm looking at a particular legal thing, I tend to ask Claude. I'm like, “Can you just explain this?” or upload a contract or whatever. Although it is not legal advice, it can be quite useful. So give us your thoughts on using AI as a sidekick in your author business and also for wider life. Suzanne: I now struggle to think what life would be like without Claude. I don't use Claude to write, at all, because I have a very particular voice and a turn of phrase, and if ever Claude writes something for me, it doesn't sound like me. It flattens me, and it makes me sound a bit American. So I don't do that. I've used it in the back end of the business. For instance, my blog was down, and there was something called a recursive bot, which I don't even know what it was, and Claude helped me fix it for free. I went through, I did screenshots. When I did an ElevenLabs audiobook and did it all myself, I was literally, for every screenshot, showing it to Claude. Claude said, “Do this, press this, press that.” So I have all these different projects set up. One is the control room, where it's for my strategic thinking. If I have an idea, I want to think about something, I put it in there. I have the engine room, which is for everything techy. Like when I had the recursive bot, or if I'm wanting to have some code on the website to make it look a particular way. Then I have other things for different subjects, and I put all the resources in there, and I use it a lot as a thinking partner. I've noticed that Fable doesn't hallucinate as much, but the Opus used to. There's something called rental discrimination, and it was proofreading and said, “No, it's not rental discrimination, it's rental income discrimination,” and that was just a load of rubbish. So I would never let it go and change things without me looking at it. I went on one of your webinars a month or so ago about MCPs and all the connectors, which is fantastic. It can go into my community and pull out all the questions for one of my live streams and put it into a document in order, by theme, for instance. It can look at my MailerLite, because that's where my newsletter is with, and analyse the different open rates and click rates and things. It's so good for analysing everything, all the book sales. It helped me with my negotiation with Penguin, and it is pretty good on law. It has sometimes hallucinated things, but not so much now. I think with anything, you've always got to go back to the primary source, and this is what we learn in academia: you have to check the primary source yourself. I have a bit of a magpie brain. I'm very much a discovery writer, like you, and things occur to me as I'm doing it. I think that Claude, at the moment, is incredible. I've been quite open about it on social media that I have Claude as a business partner. I'm a solopreneur, or whatever the word is. I have quite a big business now, and lots of different things, and it's just me doing it, because I can ask Claude how to do this, and how to do that. Claude can go and check my emails and tell me, is there somebody I've not replied to, which helps a lot. Jo: Yes. I think it's empowering as a solopreneur as such. You talk there about the fixing the tech stuff. I have my web host come to me and say, “Look, you're getting so much traffic and bot stuff, and we need to put this thing in, and it's going to be $120 extra a month.” I was like, “Can you just give me an hour? I'll get back to you.” And then I just had Claude code up, and I was like, “Analyse this and tell me what we can do.” It was like, “No, you just need to flip this switch and do that.” And I'm like, “Okay, fair enough.” Then the guy said, “Oh, no, okay, actually you don't need it.” Just stuff like that. As a solopreneur, you're either going to pay somebody technically quite a lot of money, or you can get Claude or ChatGPT. We should say, the ChatGPT Sol is very good, like the Claude Fable, for example. So, yes, using it as a sidekick. I love your control room and your engine room projects as well. That's a great way of doing it. Suzanne: I wouldn't be without it now, and I would have published the book a lot later without Claude, because Claude was helping me with the Shopify store and all the many steps of things. It saved me real time. It is just fantastic. I think, like now when I'm updating my blog, I have a connection between Claude and my blog. Claude can go in, I can give it my Google Search Console results for the page: what should I change, are the headings right? All this kind of thing. And it will give me a view on every single page, which is incredible. Jo: And YouTube, and just everything. Just super useful for that business sidekick. That's what I want authors to think. I feel like authors get so obsessed with the creative side with AI, whereas actually, people like you and me, we're using it as that engine room for the solo business, which is what I love. So we're out of time. I did want to ask one more thing, which is, one of the biggest issues with a specific book like yours is when they change the law again. So do you have a plan in place for if, say, a new government changes the law again? Will you just be updating the book over time? Suzanne: I think that there'll need to be a new edition of the book in three years' time, and I've spoken to Penguin about it. Not all of this new law has been implemented, and there's going to be case law and things. So I expect that I will update the book every few years. I have some other ideas for books as well, but for the moment, I'm just taking a bit of a break. You always say we've got to refill our creative well. I really feel like that at the moment. Recently I've just got myself a personal mobile phone so that I can turn off my work one when I'm on holiday and actually take time off. Because for all the time that I was doing the book, basically from Christmas until May, I didn't have one day off. That is not good. So I'm just trying to be a bit more balanced. I had an idea to write another book for summer, but I've just decided not to, and I'm going to leave it until I feel the urge again. Jo: Oh, well done. Suzanne: Which will come. Jo: Yes, well done. Suzanne: I think there's nothing wrong with that. We just need to think what's right for us. I'm 58. So I want to be able to have time to enjoy things and not be working all the time. Jo: No, that's great. It's a sustainable business. So where can people find you and the book and your community online? Suzanne: The easiest way to find me is theindependentlandlord.com. Or if you put Suzanne Smith and landlord into Google, you'll find me as well, and there's a link on there to the book, The Good Landlord Handbook. In the community, there's a link to that on my website as well. Jo: Brilliant. Well, thanks so much for your time, Suzanne. That was great. Suzanne: Thank you.The post From Blog To Community To Book: A Non-Fiction Author's Journey With Suzanne Smith first appeared on The Creative Penn.

As fear spreads through Sacramento, the public demands answers. Communities hold meetings. Newspapers cover the case. And all the while, Paul Holes believes the East Area Rapist was likely watching closely. In this episode, we examine a chilling turning point in the series: the first known attack with a man present in the home, and the possibility that the offender targeted that couple after a town hall comment. The case draws more public attention, and the crimes become more calculated. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of events that underscore the dynamic nature of these industries, characterized by scientific advancements, strategic partnerships, and regulatory milestones. Johnson & Johnson has made headlines with its substantial $785 million upfront payment to Sail BioMed for an in vivo CAR-T cell therapy deal. This agreement includes an option for Johnson & Johnson to acquire Sail BioMed for $2.58 billion, underscoring the sustained interest in cell therapies, particularly for autoimmune diseases. In vivo CAR-T therapies represent a significant leap forward by modifying T cells directly within the patient's body. This method offers potential advantages over traditional ex vivo techniques by simplifying the manufacturing process and potentially reducing both costs and time to treatment. Such transactions highlight Johnson & Johnson's commitment to expanding its cell therapy portfolio, which could significantly enhance patient care by making advanced treatments more accessible. Eli Lilly and Resilience have announced a significant $750 million investment aimed at boosting the production of diabetes and obesity medications in the United States. This move comes as a response to the global rise in these conditions, necessitating increased production capacities to meet growing demand. The focus on injectable drug devices emphasizes efforts to improve drug delivery systems, ultimately enhancing patient compliance and therapeutic outcomes. Sanofi's financial outlook for 2026 is promising, driven by robust sales of Dupixent, which exceeded €5 billion in quarterly sales. Dupixent, a monoclonal antibody used for treating atopic dermatitis and other autoimmune conditions, has been a significant revenue driver for Sanofi. The success of Dupixent reflects its effectiveness and strong market adoption, highlighting the potential of monoclonal antibodies as cornerstones of modern pharmacotherapy, particularly for chronic inflammatory diseases. Regeneron and Sanofi's Dupixent continues performing strongly with $6 billion in sales during Q2 2026—marking its largest quarterly revenue since the pandemic began—illustrating robust demand across various indications within both companies' portfolios. On the regulatory front, Alfasigma's Linerixibat (Lynavoy) has received a positive opinion from the CHMP for treating cholestatic pruritus in primary biliary cholangitis following successful Phase 3 trials. As an IBAT inhibitor targeting bile acid metabolism pathways, Lynavoy introduces a novel therapeutic approach for managing symptoms associated with this autoimmune liver disease. Meanwhile, ImmunityBio's Anktiva has gained marketing authorization in the UAE for non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. Anktiva, an IL-15 cytokine-based protein therapy, exemplifies the growing interest in harnessing immune system modulators for cancer treatment. Takeda's recent decision to discontinue its nanoparticle therapy (TAK-101) for celiac disease highlights the inherent challenges in developing new therapies for autoimmune disorders. The disappointing Phase 2 results suggest that achieving immune tolerance to dietary gluten remains a significant scientific hurdle. From a strategic perspective, Sanofi's CEO has emphasized stricter go/no-go decisions during Phase 3 clinical trials amid pipeline cuts and significant impairment losses. This approach could lead to more efficient resource allocation and potentially higher success rates for late-stage drug candidates. The industry is witnessing significant transformations through strategic shifts driven by executives like Sanofi's new CEO Belen Garijo. Her vision includes reversing recent challenges faced by Sanofi by capitalizing on its strengths while addressing setbacks such as discontinuing certain late-stage clinical programs like the joint venture with Regeneron on the IL-33 candidate itepekimab. This strategic pivot mirrors broader industry trends toward optimizing late-stage pipelines to enhance competitive positioning and drive future growth. Advancements in AI-powered drug discovery continue gaining momentum through collaborations like those between GSK and Relation Therapeutics, alongside Causaly and Sage. These partnerships aim to leverage AI and machine learning technologies to accelerate drug discovery processes by integrating vast amounts of scientific literature into data analytics platforms. GlaxoSmithKline's $110 million deal with an AI biotech firm further signals increased integration between artificial intelligence technologies and pharmaceutical research efforts aimed at enhancing dataset quality thereby accelerating innovation throughout drug discovery processes. Bristol Myers Squibb faces further delays regarding its Alzheimer's psychosis treatment Cobenfy—a postponement reflecting ongoing complexities related to neurological drug development which requires overcoming high scientific hurdles alongside regulatory scrutiny. Alnylam Pharmaceuticals recently experienced a 29% drop in stock value following disappointing sales of Amvuttra and a downward revision of its ATTR franchise outlook for 2026. Such fluctuations highlight volatility within biotech investments when market expectations are not met. These collective developments reveal significant trends shaping today's pharmaceutical landscape: strategic pipeline optimization efforts alongside robust investment initiatives targeting high-demand therapeutic areas—all while leveraging technological advancements like AI integration aimed at improving R&D efficiency ultimately impacting patient care worldwide through innovative therapies addressing unmet medical needs globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the latest news shaping these dynamic sectors, exploring strategic corporate maneuvers, groundbreaking scientific advances, and pivotal regulatory changes. GlaxoSmithKline (GSK) is embarking on a comprehensive restructuring initiative aimed at achieving $2.5 billion in annual cost savings by 2029. This ambitious initiative underscores the company's commitment to strengthening its late-stage research and development capabilities. The strategy involves optimizing mature product lines, procurement processes, and supply chain efficiencies, reflecting broader industry trends where financial prudence is balanced with innovation. As part of this transformation, GSK plans to relocate its research headquarters near AstraZeneca's facilities, though specifics on employment impacts remain under wraps. This restructuring highlights the competitive nature of the pharmaceutical landscape and GSK's intent to maintain its edge through enhanced R&D initiatives. Meanwhile, Johnson & Johnson is nearing a resolution in its extensive talc litigation by proposing a $5.5 billion settlement to resolve approximately 76,000 lawsuits. These lawsuits allege that J&J's talc-based baby powder caused ovarian cancer. This potential settlement represents a significant step toward closing a protracted chapter of legal scrutiny for J&J, offering the company a chance to mitigate ongoing legal risks and refocus on core business operations. On the regulatory front, MannKind has secured FDA approval for its fast-acting edema autoinjector, reflecting an ongoing emphasis on addressing unmet medical needs with innovative delivery mechanisms. Conversely, Baxter has issued a recall for one lot of cefazolin in dextrose injection due to contamination concerns, underscoring the continuous challenges of ensuring product safety within complex manufacturing and supply chain environments. In terms of public health initiatives, Gilead Sciences is employing a novel approach to HIV prevention through its "Up to Date" campaign featuring comedians Nicole Byer and Devon Walker. This effort aims to destigmatize HIV discussions within the Black community by leveraging humor and relatability—a testament to evolving strategies in patient engagement and education. In drug development news, Atea Pharmaceuticals is making strides with its hepatitis C treatment candidate following positive Phase 3 trial results showing equivalence with Gilead's Epclusa. This positions Atea for further clinical evaluations and potential market entry with a simplified treatment regimen. Similarly, Hansoh Pharmaceutical's collaboration with GSK has yielded another Phase 3 success for their B7-H3-directed antibody-drug conjugate in China, highlighting the growing importance of targeted therapies in oncology. Emerging biotech hubs are reshaping the industry's landscape as cities beyond traditional centers like Boston and San Francisco gain prominence. This geographical diversification reflects global trends in biotech innovation and investment. In clinical advancements, Altimmune's GLP-1/glucagon receptor-targeting drug shows promise in reducing heavy drinking among individuals with alcohol use disorder (AUD). This finding opens new therapeutic avenues for AUD by leveraging mechanisms traditionally associated with weight loss medications. Concurrently, regulatory scrutiny remains high as Replimune faces setbacks with its melanoma data package deemed "not interpretable" by the FDA—an indication of the rigorous standards required for gaining regulatory approval. The geopolitical landscape also influences industry dynamics, particularly in China where intellectual property risks are heightened under new legislative acts. Companies must navigate these complexities strategically to protect innovations while capitalizing on market opportunities. Financially, Novo Holdings-backed Claris has secured $118 million in Series B funding to advance its corneal disease drug candidate—a substantial investment underscoring growing interest in ophthalmology therapeutics. Additionally, RA Capital has launched Oak Hill Bio onto Nasdaq via a special purpose acquisition company (SPAC), focusing on rare genetic diseases—a strategy showcasing continued momentum within biotech to leverage financial tools for niche therapeutic advancements. Overall, these developments reflect an industry characterized by rapid scientific progress and evolving regulatory landscapes. Companies are under pressure to optimize operations while ensuring robust clinical data to meet regulatory standards. As these sectors strive for innovation and patient care advancements amidst competitive global markets, balancing innovation with safety and efficacy remains paramount. As always, we'll continue to track these stories closely and bring you the latest insights right here on Pharma Daily.Support the show

The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics' Duchenne muscular dystrophy therapy and Replimune's advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.

US President Trump said Iran is talking to the US about making a deal right now and very friendly talks are ongoing, while he added they will end Iran's nuclear threat very quickly and that Iran is behaving again.US President Trump said Iran wanted to meet and that "we're meeting," while he added there is a chance a deal could be reached.APAC stocks were mostly negative amid a tech bloodbath and competition concerns following reports yesterday that China had started mass production of domestically developed DUV lithography equipment.DXY traded little changed, 10yr UST futures traded range-bound, and Crude futures remained subdued overnight.European equity futures indicate a flat cash market open, with Euro Stoxx 50 futures little changed after the cash market closed flat on Monday.Looking ahead, highlights include Spanish Retail Sales (Jun), US ADP Employment Change Weekly, Goods Trade Balance Advance (Jun), Retail Inventories Ex Autos Advance (Jun), Wholesale Inventories Advance (Jun), Consumer Confidence, Atlanta Fed GDP (Q2), Supply from UK, Italy, Netherlands & US, Earnings from PayPal, Boeing, UPS, Ford, EssilorLuxottica, Kering, Air Liquide, Eni, Barclays, GSK & Unilever.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

The case moves into Cordova Meadows, a Sacramento-area neighborhood that became key to understanding the East Area Rapist. Through maps, geography, victimology, and old case files, Paul Holes explains how the offender's movements revealed familiarity, planning, and confidence. What may have looked random from the outside begins to look very different when Paul studies the streets, fences, backyards, and anchor points that help shape the investigation. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules. The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever. To learn more about the topics in this episode: GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong House passes bill directing FDA to update animal testing rules See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting scientific breakthroughs and regulatory developments that are shaping the future of healthcare. Eli Lilly's retatrutide, a promising small molecule GLP-1 receptor agonist, has achieved significant results in Phase 3 trials, leading to an impressive 22.6% weight loss in patients with obesity and cardiovascular disease. This breakthrough underscores the potential of GLP-1 receptor agonists in transforming treatment paradigms for metabolic disorders. The drug's ability to target metabolic pathways associated with obesity and type 2 diabetes could herald a new era in managing these conditions, offering hope for millions struggling with obesity—a major risk factor for cardiovascular diseases. In oncology, Johnson & Johnson has unveiled remarkable results with its combination therapy of Tecvayli (teclistamab) and Talvey (talquetamab), achieving an 89% reduction in disease progression risk for multiple myeloma patients during a Phase 3 trial. This bispecific antibody approach targets BCMA and GPRC5D, representing a significant advancement in treating this challenging hematological malignancy. Such efficacy could set a new standard for multiple myeloma treatment strategies, enhancing patient outcomes considerably. Meanwhile, GSK has made strides with FDA approval of Jideytro (zidesamtinib) for ROS1-positive metastatic non-small cell lung cancer. This small molecule kinase inhibitor targets the ROS1 mutation, providing a targeted therapeutic option that aligns with the progress in precision medicine—offering treatments based on patients' genetic profiles. On the regulatory front, the passage of FDA Modernization Act 3.0 by the House reflects a shift towards more ethical preclinical testing methods by updating outdated animal testing regulations. This legislative change could expedite drug development timelines and improve the translation of preclinical findings into clinical success—an encouraging step forward for the industry. In China, Takeda's Orzeyful (oveporexton) received approval as the first ox2r agonist for narcolepsy type 1 treatment. This approval marks advancements in addressing neurological conditions through novel mechanisms targeting orexin receptor pathways. Similarly, Haisco Pharmaceutical's Ciprocopan has been approved as an oral complement factor B inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), offering a more convenient treatment option compared to existing therapies. AstraZeneca's Etcamah (camizestrant) gained EU approval following its success in Phase 3 trials for estrogen receptor-positive, HER2-negative advanced breast cancer. As an oral selective estrogen receptor degrader (SERD), it presents an innovative approach to targeting ESR1 mutations and could be combined with CDK4/6 inhibitors to enhance therapeutic efficacy further. On the strategic collaboration front, partnerships like those formed by Arcus Biosciences with Aveo Oncology and Summit Therapeutics exemplify efforts to advance drug discovery capabilities, particularly in kidney cancer treatments. These collaborative approaches reflect a broader trend in oncology therapeutics development. Financial investments are also fueling growth within the sector. Mentari Therapeutics secured $200 million to propel its migraine prevention biologics pipeline forward, highlighting confidence in biologic treatments for neurological disorders. Beone Medicines has committed $300 million to expand manufacturing capabilities, demonstrating ongoing investment in infrastructure to support future drug production demands. In summary, these developments illustrate significant scientific advancements and regulatory progress within the pharmaceutical and biotech industries. The implications are profound: improved patient care through innovative therapies, enhanced precision medicine approaches tailored to genetic mutations, and accelerated drug discovery processes facilitated by evolving regulatory frameworks. As these trends continue to evolve, they promise to reshape patient outcomes and redefine standards across various therapeutic areas. Thank you for tuning into Pharma Daily today. Stay informed as we continue to bring you updates on cutting-edge advances that are transforming healthcare worldwide.Support the show

Aurélia Nguyen, Dep. CEO of CEPI (Coalition of Epidemic Preparedness Innovations) shares her unusual personal and career story, including working with Andrew Witty at GSK, and with Seth Berkley at GAVI during Ebola in West Africa 2014-2015 and later during the COVID-19 pandemic when she managed the COVAX facility. "It was incredibly difficult." CEPI's 3.0 strategy focuses on viral families; technologies and platforms; and networks to rapidly conduct clinical trials and begin manufacturing. CEPI swung rapidly into action with the advent of the Bundibugyo Ebola outbreak in Ituri, DRC. It struck a promising $50 million partnership with the Department of State in support of its work to accelerate development of four vaccine candidates. Clinical trials are beginning and will advance in the fall in the hot zone in eastern DRC. Mistrust and insecurity require intensive community engagement. Even with US and EU support, CEPI still strives to fill an estimated $130 million gap over the next 6-9 months. Her biggest worry? Cases have doubled in just 23 days. We are not yet able to gauge the true scale of the outbreak. 

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Co-hosts Ryan Piansky, a patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Dr. Claire Beveridge about EoE and dysphagia. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:49] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:17] Holly introduces today's topic, research on eosinophilic esophagitis (EoE) and dysphagia.   [1:24] Holly introduces and welcomes today's guest, Dr. Claire Beveridge, a gastroenterologist at the Cleveland Clinic. Dr. Beveridge heads the EoE Adult Clinic and the Transition from Pediatric to Adult EoE Clinic.   [1:36] Holly, a speech pathologist, says she is very excited to dive into the research Dr. Beveridge did with EoE and dysphagia. Holly asks Dr. Beveridge to share some of her background.   [1:48] Dr. Beveridge was recruited to the Cleveland Clinic about five years ago to head the EoE Center. She loves the work they have done there.   [1:57] Dr. Beveridge says it's been nice to center everything on their EoE patients and have multidisciplinary care with speech-language pathologists, allergists, dietitians, pulmonologists, and more. It's been a great experience.   [2:15] Dr. Beveridge says the other thing they are really proud of is having a Transition Clinic. It can be tough for patients to transition from pediatric to adult care.   [2:23] Dr. Beveridge says this is something she was inspired to do when she was finishing her training at the University of Pennsylvania, where they had been doing some of that. It was really important to her when she joined Cleveland Clinic.   [2:34] Dr. Beveridge, with her Co-director, Dr. Sophia Patel, helps patients transition from pediatric to adult care.   [2:41] Holly speaks of the challenge of transitioning from pediatric care at a multidisciplinary clinic to adult care.   [3:08] Dr. Beveridge says you can't do any training at Northwestern without loving the esophagus. She did her residency there, got exposed to esophagology, and got to know Dr. Gonsalves and Dr. Hirano really well.   [3:33] Drs. Gonsalves and Hirano are really big names in EoE. Dr. Beveridge was fascinated by the disease. She loved the patients and wanted to help them and make them feel better. It's a burgeoning field.   [3:48] Dr. Beveridge says that it's only in the last few years that we have had FDA-approved medications for it, and that we have been jerry-rigging asthma medications to treat our patients.   [4:03] Dr. Beveridge says it's really exciting to see the treatment options we can offer.   [4:10] Ryan says it's exciting to see how EoE management has changed.   [4:16] Ryan says we see so many patients who are untreated or poorly treated for years, who have restructuring of their esophagus and present with dysphagia, or have strictures and rings leading to food impactions; the long-term effects of untreated EoE.   [4:34] Ryan says it's exciting that now we do have better treatment options for people, right off the bat.   [4:43] Dr. Beveridge conducted some research on EoE and dysphagia and presented a poster at the 2024 Digestive Diseases Week.   [4:51] The poster was titled, "Esophageal Luminal Diameter is Associated with Dysphagia and Eosinophilic Esophagitis: Implications for Endoscopic Dilation Therapy."   [5:11] Dr. Beveridge says dysphagia means issues with swallowing. It's a feeling of something getting stuck or something slowly moving down. There are also subtle symptoms that can happen.   [5:31] Dr. Beveridge says patients who have had EoE for a long time become accustomed to how they swallow. Things a patient may think are normal, like needing water and taking a sip after each bite, are learned accommodating behaviors.   [5:58] Dr. Beveridge says accommodating behaviors are that you're needing to imbibe extra water, you're modifying how you're eating, extra chewing, avoiding pills, avoiding other certain foods, and things like that that can be modifying factors.   [6:19] So, difficulty with swallowing, things getting stuck, slowly moving down, but also keeping in mind some of those modifying behaviors that we may end up using.   [7:23] Dr. Beveridge says her motivation was seeing patients in her clinic who were having persistent symptoms, and getting them into histological remission. The goal of treating your EoE is to get the eosinophils less than 15; close to zero is great.   [7:45] Dr. Beveridge says we have patients who, despite doing their endoscopies and taking biopsies, things look fine; they're still having issues with swallowing. Why is that the case?   [7:58] Dr. Beveridge says in a different research paper she had done, looking at some of the predictors for that, one of them was fibrostenosis. There are also other things that can contribute, like esophageal hypervigilance and a fear of swallowing.   [8:21] If a patient has had a food impaction, it's going to be scary to try to swallow again. Some of it is behavioral, but some of it is structural. At what luminal diameter (the size of the esophagus) is that causing a clinical problem for patients?   [8:45] A normal esophagus is 20 to 24 mm in diameter. Traditionally, around 14 to 16 mm in diameter has been when we say that patients get symptoms or they're feeling the issues with swallowing.   [9:03] Dr. Beveridge says a lot of those studies have never been done specifically for EoE patients.   [9:08] Dr. Beveridge wanted to know, if we exclude cancer, if we exclude acid reflux, and all of these other things, and just look at our EoE patients, what size of the esophagus are we looking at?   [9:20] Dr. Beveridge explained they specifically looked at patients whose histology was under control and then compared those who continued to experience symptoms with those who did not. The goal was to determine the histologic threshold at which patients begin to experience dysphagia.    [9:54] Dr. Beveridge says they saw this threshold at 16 mm (1.6 cm). That's still quite the difference from a normal esophagus of 20 to 24.   [10:08] Dr. Beveridge says our esophagus can definitely handle being smaller, but then, once you get to that 16 mm, for a lot of patients, it really does cause that feeling of things getting stuck or slowly moving down.   [10:20] Holly says what's cool about the retrospective data Dr. Beveridge looked at, and the parameters she placed in the research, is that when a patient goes in for an endoscopy, the doctor can measure and say maybe this is why dysphagia is going on.   [10:48] Holly finds that adult patients with food impactions are scared to eat the same food again. She loves having this data to share with patients and say, let's look at what your esophagus measures at. Let's do a smaller bite. Let's add a dip and liquid.   [11:12] Holly says data can push so much progress. Holly, having multiple chronic illnesses, loves when doctors can say, this is going to be safe. This is the mode that we're going to go with.   [11:30] Dr. Beveridge says in the retrospective study, they were looking at stuff that had already been done. We decided from here to assess patients more prospectively. All of this was based on chart review from when the note said symptoms or no symptoms.   [11:53] Dr. Beveridge says when she started this EoE clinic at the Cleveland Clinic, part of it was to standardize better how we were collecting data from patients to understand their symptoms.   [12:07] Dr. Beveridge has a standardized questionnaire for patients to understand if they are having heartburn and difficulty with swallowing, so she can know that at each point of their endoscopy.   [12:18] Dr. Beveridge says it will be nice, hopefully in the future, when she can give a little more detail and depth in terms of assessing this more prospectively and seeing if that same number holds up or if she needs to tweak it a little bit.   [12:34] Holly thinks it's fascinating. Numbers give us so much information, to know if my mm is this versus this, the next time, or during allergy season or not.   [12:53] Ryan says it's cool that you're able to look back at existing patient records and identify this information. Now we have that 16 mm number in mind to say maybe this is where we'll start to see increased risk of dysphagia in these patients.   [13:28] Dr. Beveridge says, how we had to do it retrospectively was based on the endoscopist estimating what the size is. Gastroenterologists recognize they're not always the best at estimating the size of the esophagus.   [13:50] Dr. Beveridge says, if your endoscope could not pass through, or it was snugly passing through, you know the diameter of the endoscope. If a dilation was done, at what size dilation do we start to see a disruption?   [14:19] Dr. Beveridge says, the goal of a dilation is to get a disruption because there's scar tissue we want to break open. A patient might think disruption means a perforation or something more scary, but that is the goal. We want to break open that scar tissue.   [14:42] Dr. Beveridge says, once we see that scar tissue break open a little bit, then we can estimate what the diameter is, based on the size dilator we used.   [15:10] Dr. Beveridge says for adults, we use a standard adult upper endoscope, and that's about 13 mm. The ones we use for kids are about 6 mm.   [15:35] Dr. Beveridge says the adult endoscope is around 13 mm, and it's around 14 to 16 mm when we start to see the symptoms.   [16:07] Dr. Beveridge says there are two main types of dilation that we do. One is the Savary dilator or wire-guided dilator, a long dilator that stretches the entire esophagus, from the mouth down to the stomach.   [17:20] Dr. Beveridge says another way of doing it is while you have the endoscope in, you thread a catheter. At the end of the endoscope, there's a balloon. You fill the balloon with saline up to different sizes. Typically, they go up by 3 mm, so 12 to 15 mm.   [18:01] Dr. Beveridge says the catheter balloon dilator is good for discrete strictures because the balloon isn't going to do the entire esophagus; it's just going to do one area of the esophagus, and you're watching it the whole time.   [18:19] For the wire dilator, you remove the scope. You're not able to see, so it's important to assess ahead of time how narrow things are, so you start at a safe dilation. You go in each time to see if there's starting to be disruption, and then you can do more.   [18:44] Holly asks if a gastroenterologist doing an upper endoscopy with sedation sees that it's tight, would the gastroenterologist automatically do a dilation? Or, can a patient with dysphagia symptoms request to have a dilation?   [19:28] Dr. Beveridge says, right before an endoscopy, she discusses it with the patient and gets consent. She asks, even if their symptoms are good, but in the endoscopy she sees a narrowing where she would recommend a dilation, if they're OK with that.   [20:05] Dr. Beveridge says, if they're having issues with swallowing, often she will ask if they're OK with her doing a dilation. If she sees a narrowing, she can focus on that area and dilate it.   [20:19] Dr. Beveridge says not everywhere in the esophagus can we see as well. The very beginning of the esophagus is challenging to see and challenging to evaluate on imaging.   [20:32] Dr. Beveridge talks about empiric dilation. You don't see a narrowing, but you want to rule it out, so you do a dilation at a safe size, like 16 or 18 mm, to make sure you're not missing something up high.   [20:58] Dr. Beveridge says she always talks about that with her patients. Most say, go ahead. Some patients definitely want dilation; other patients say no, they really don't.   [21:12] Dr. Beveridge then asks the patient if there's real narrowing that may cause a food impaction, would they want dilation then, or hold off for another day?   [21:30] Dr. Beveridge never wants to do something the patient is not comfortable with. She also doesn't want them to need another endoscopy unnecessarily, if she can avoid that for them in the moment.   [21:46] Dr. Beveridge mentions the BougieCap used in Europe. It's a cap you put at the end of the endoscope. You use your endoscope as the dilator. You watch the whole time. It is hard plastic that causes a nice dilation. We may see it come to the U.S.   [22:37] Dr. Beveridge speaks of the FLIP catheter, which is a catheter with a balloon that doesn't cause dilation but distends and helps measure the diameter.   [23:33] Holly asks if Dr. Beveridge gives tips to patients on how to prepare for dilation and the recovery process.   [23:49] Dr. Beveridge had an upper endoscopy. She says there's nothing like experience to understand it better. She didn't have a dilation, but the biopsies caused discomfort.    [24:21] Dr. Beveridge says a lot of her patients have been through upper endoscopies, so they know how it feels. She warns them that the biopsies and dilation can cause discomfort.   [24:33] What's challenging is that everyone is different. Some patients are going to be more hypersensitive to it, and other patients are going to say they felt nothing and they were fine.   [24:46] Dr. Beveridge says some patients need to modify their diet for a few days to avoid significant chest pain. You never want someone to have to go to the ER for significant chest pain when it will just heal over time, and there's no perforation.   [25:12] Dr. Beveridge says other patients will be like her, eating chips and pretzels and saying they're fine. Dr. Beveridge typically has them start with liquids, nothing too hot or too cold, and advance as tolerated.   [25:28] Dr. Beveridge says patients can always use TylenolⓇ and over-the-counter numbing agents. You'll still have patients who will get significant discomfort. For the most part, starting with liquids has worked for Dr. Beveridge's patients.   [25:44] Holly recommends over-the-counter when her patients call, after she talks to their GI. Holly says after she has an endoscopy, she starts on liquids and shakes. On day three, she's fine. Holly says individualized care is amazing. We all are different.   [26:14] In the pediatric setting, the parents get the counseling, and they have not had sedation, but on the adult side, you're talking with the patient, who had sedation. Sometimes they don't remember.   [26:40] Dr. Beveridge says when possible, she waits for family members to come back and tells them they're going to have to "be the memory" because the patient probably won't remember this conversation.   [26:55] If a patient says no, they don't want them to come back and hear about it, always respect that. But Dr. Beveridge always tells them, you may not remember what we say.   [27:30] Ryan asks about data on how many times someone may need dilations. Dr. Beveridge says it comes down to the patient, but the biggest issue can be uncontrolled inflammation.   [27:44] Dr. Beveridge says if a patient's EoE is not controlled, inflammation leads to continued scarring down. That's why we talk about dilation as being an adjunctive measure, but not a treatment for EoE. It doesn't do anything for the inflammation.   [28:03] Dr. Beveridge says she has patients who ask why she can't just do a dilation every now and then. Dr. Beveridge considers dilation to be safe when needed, but if you can avoid it, that would be nicer for everyone.   [28:21] Dr. Beveridge says there's no great data on whether you only need one, or whether you're going to need 10, but one big theme is just: have we gotten your inflammation under control? That's also true for other conditions, such as acid reflux.   [28:45] Holly wasn't diagnosed until she was in her mid-twenties, and she had several upper endoscopies as a teenager and college student to dilate her, to help the situation.   [29:17] Holly says she had to get more endoscopies to figure out her weird food triggers that are not typical for everybody, so even if she's treated, she still has inflammation. That's why she had so many upper endoscopies.   [29:30] Ryan talks about underlying issues causing inflammation. Dilation is not treating those underlying causes. It's just helping with one symptom of this dysphagia, by expanding the esophagus.   [29:50] Ryan asks, What changes in symptoms should patients expect after the dilation? Dr. Beveridge says, ideally, if there's been a stricture, you're going to start to feel like your swallowing is better. You can get pills and food down better.   [30:07] Dr. Beveridge says, immediately post-dilation, sometimes people feel a little bit worse. Everything you swallow may be uncomfortable for you. But if it's been a successful dilation, hopefully, you're going to feel that things are going down better.   [30:40] Holly says she is so grateful that Dr. Beveridge looked into this, and hopefully, there will be a new protocol in the future. Holly asks what other key takeaways from this research may interest Dr. Beveridge in researching something further.   [31:02] Dr. Beveridge says, making sure that we're not missing scar tissue is big and important. One thing that we're trying to look at with our Pediatric GI colleagues is what threshold we should be looking at for the pediatric patient population.   [31:19] Dr. Beveridge says a pediatric patient's esophagus is a different size than an adult patient's. Understandably, we are more cautious when doing a dilation in the pediatric patient population than we are with adults.   [31:34] Dr. Beveridge may recommend empiric dilation for an adult but will feel more cautious about that with pediatric patients than with adult patients. Understanding what that threshold should be for the pediatrics is going to be really interesting.   [31:57] Dr. Beveridge says the diameter threshold we discussed is going to be important to know about, but everyone is different. You may have a diameter of 14 mm, you feel fine, and you don't want a dilation; you can accommodate OK. That's reasonable.   [32:15] Dr. Beveridge says she has had patients who get up to 18 mm, and that helps them, but they need a little bit more. If someone needs more of a dilation, we do that. Yes, have a threshold to assess, but always assess for what's personal for your patient.   [33:04] Dr. Beveridge says not just to assess the luminal diameter, but a thing that is helpful for gastroenterologists to know will be if there are other factors at play. As in her study of dysphagia predictors, anxiety, depression, and hypervigilance can play roles.   [33:37] Dr. Beveridge has patients who have to have a critical narrowing for them to finally feel an issue. Other patients, if they have the slightest of narrowing, are feeling something. Some patients are just more vigilant of what's happening in their esophagus.   [34:07] Dr. Beveridge says there's definitely a role for asking if your anxiety is under control. If there's feedback in the nerves, should we ask your GI Psychologist to be involved in terms of CBT for your esophagus? Take a look at everything.   [34:27] Dr. Beveridge says another part of the study they looked at was: are there different thresholds of eosinophils that we should be looking at? Is it just less than 15, or do some patients need it to be lower? Less than six? Less than 10?   [34:43] Dr. Beveridge says look at it as a whole for your patient.   [34:53] Dr. Beveridge says next, she will be working on a very long-term project: Can we identify a non-invasive method of screening a patient, diagnosing a patient for EoE, or monitoring a response to therapy?   [35:13] Dr. Beveridge has looked at transnasal endoscopy, which is put into this category of minimally invasive. It's still invasive; you're putting a scope through someone's nose, but it doesn't require sedation, which is a nice thing for some patients.   [35:29] There's the EnteroTrack, which started in Colorado. A patient swallows a string, and it stays in their esophagus for an hour, and we look at the proteins to see if things are active or not active.   [35:45] Dr. Beveridge is also looking at the breath metabolome. If we breathe into a bag and take a look at all the volatile organic compounds that are in our breath, can we find a signature related to EoE?   [36:01] It's assessing about 100 different compounds, not looking at one in particular, but how the whole thing looks. What signature is there, based on looking at all the compounds?   [36:15] Dr. Beveridge presented some of that data at DDW and has a grant from the ACG to look at this and assess patients with and without EoE.   [36:33] Dr. Beveridge says further, doing longitudinal data of looking at patients once they've gotten into remission on treatment and seeing, do we then see a signature change?   [36:47] Dr. Beveridge says no one is under any illusion that endoscopies are going away. They will always be part of what we do in gastroenterology, but there are limitations: sedation, a full day away from work, nothing by mouth, and a driver, etc.   [37:04] If there are alternatives to help supplement that, it would be nice. One of the barriers for patients doing diet elimination is the number of endoscopies that are required. If there's a way to assess by breath if a food is a trigger, that would be good.   [37:32] Dr. Beveridge says that's the big thing she's looking at, but it will take years. It's not going to be a quick, easy one, but it's very interesting to take a look at.   [37:45] Holly speaks of how much treatment has changed since she was diagnosed. She has done all the scopes. She says this sounds amazing. She loves that people like Dr. Beveridge are thinking of how to make testing less invasive and more comfortable.   [38:12] Dr. Beveridge says another thing she is excited about is the transition of care. She recently did a survey and is analyzing the data to assess what the barrier is from the physician perspective in terms of helping our patients transition.   [38:40] Dr. Beveridge is also looking at doing a nice multi-center consensus to help this as well, led by Dr. Sophia Patel and Dr. Emily McGowan, who are fantastic in the EoE world, looking to see how we can make this better for our patients.   [38:58] Ryan says, with so much interesting work coming up, we'll have to have you back to chat about some of these additional projects. Everyone is super interested in less invasive stuff and better treatment pathways. Transition of care is an important part of that.   [39:11] Ryan appreciates Dr. Beveridge for joining the conversation and hopes to have her back on another episode so we can learn more about EoE and these different future research endeavors.   [39:20] For our listeners who would like to learn more about EoE today, you can visit apfed.org/EoE and check out the links in the show notes below. [39:27] If you're looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder, available at apfed.org/specialist.   [39:36] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [39:46] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experience, please check out apfed.org/shareyourstory.   [39:55] Ryan thanks Dr. Beveridge for joining us. This was a fun conversation and really insightful. Holly thanks APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.orgapfed.org/specialist apfed.org/connections Claire Beveridge, MD Cleveland Clinic Education Partners: This episode of APFED's podcast is brought to you thanks to the support of AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   Tweetables (Edited):   "I have loved the work that we've done [at the Cleveland Clinic]. It's been really nice to center everything on our EoE patients and have nice multidisciplinary care with speech-language pathologists, allergists, dietitians, pulmonologists, and everyone." — Claire Beveridge, MD   "It's a little crazy to think that it's only in the last few years that we have had FDA-approved medications for [EoE], and that we have been jerry-rigging asthma medications to treat our patients." — Claire Beveridge, MD   "On the whole, dysphagia means issues with swallowing. … It's a feeling of something getting stuck or something slowly moving down. There are also subtle symptoms that can happen." — Claire Beveridge, MD   "The goal of a dilation is to get a disruption because there's scar tissue we want to break open." — Claire Beveridge, MD   "I am looking at the breath metabolome. If we breathe into a bag and take a look at all the volatile organic compounds that are in our breath, can we find a signature related to EoE?" — Claire Beveridge, MD   Guest Bio: Claire Beveridge, MD, is a Staff Member in the Department of Gastroenterology and Hepatology and heads the Eosinophilic Esophagitis (EoE) adult clinic as well as the transition pediatric to adult EoE clinic. Dr. Beveridge's specialty interests include: EoE, Achalasia, Barrett's esophagus, GERD, esophageal swallowing disorders, and esophageal motility disorders.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

The crimes move north, and a new name emerges: the East Area Rapist. Paul Holes explains how the offender's behavior changed after Visalia, how early attacks in the Sacramento area unfolded, and how investigators struggled to understand whether they were dealing with a new offender or just someone who had evolved. As the crime spree expands, Paul begins to unpack one of the most disturbing facts of the case: Joseph DeAngelo was a police officer. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us Fan MailLithium is one of those molecules most people think they understand, until you zoom out. Yes, it's a time-tested medication for bipolar disorder. But at tiny, trace doses, lithium starts to look like something else entirely: a potential micronutrient with outsized influence on mood stability, inflammation, and brain ageing.We walk through why interest in low-dose lithium is rising in the brain health and longevity world, even as human clinical trials are still early. John and I talk about what lithium is chemically, why it's so bioavailable, how it crosses the blood-brain barrier, and why the kidneys matter more at prescription doses than at supplement-scale milligrams. Then we connect the dots on mechanisms people care about most for neuroprotection: GSK-3 inhibition, support for BDNF, a tilt toward calming inhibitory signalling (GABA), better balance in serotonin pathways, and less glutamate-driven mitochondrial stress.We also wrestle with the bigger public health angle: what happens when we treat chronic disease as “too much of everything” and ignore deficiency and nourishment. Soil mineral depletion, variable food mineral content, and strong population associations with lithium in drinking water (including mental health measures and Alzheimer's mortality) make this a conversation worth having, carefully and objectively.For slides and open-source references: www.thehealthedgepodcast.comIf this sparks questions for you, subscribe, share it with a friend, and leave a review so more people can find the show.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

Rhonda Swan is a global brand strategist, public relations executive, best-selling author, and the Founder and CEO of the Unstoppable Branding Agency (UBA).The Corporate Shift to Digital PioneerRhonda began her career in corporate America, holding an MBA and working as a high-level marketing executive for a Fortune 100 pharmaceutical company (GSK), where she managed massive multi-quarter advertising budgets. Driven by a desire to prioritize family and lifestyle freedom over traditional corporate life, she made the bold choice to leave her corporate job in the mid-2000s. She quickly built a digital marketing infrastructure, famously becoming one of the early female entrepreneurs to scale an online business to over 7 figures using automated sales funnels.The Unstoppable Legacy & Media FootprintThe Agency: Alongside her husband, Brian Swan, she founded the Unstoppable Branding Agency.

Paul Holes begins the story in 1970s Visalia, California, when the Golden State Killer was just beginning to make a name for himself. Before the East Area Rapist, before the Original Night Stalker, there was the Visalia Ransacker, a prolific offender breaking into homes and leaving fear behind. Paul walks Yeardley, Dan, and Dave through the early crimes, the killing of Claude Snelling, the shooting of Officer McGowan, and the case files that first pulled Paul into what would become a career-defining 24-year pursuit. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SXA865. CME/MOC/AAPA/IPCE credit will be available until June 15, 2027.Breaking Barriers in cUTI Care: Integrating Novel Oral Therapies and Transitions of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SXA865. CME/MOC/AAPA/IPCE credit will be available until June 15, 2027.Breaking Barriers in cUTI Care: Integrating Novel Oral Therapies and Transitions of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SXA865. CME/MOC/AAPA/IPCE credit will be available until June 15, 2027.Breaking Barriers in cUTI Care: Integrating Novel Oral Therapies and Transitions of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SXA865. CME/MOC/AAPA/IPCE credit will be available until June 15, 2027.Breaking Barriers in cUTI Care: Integrating Novel Oral Therapies and Transitions of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

In this episode, podcast co-hosts Dr. Dwight Stoll and Dr. James Grinias talk with two recent award winners live from the Pittcon conference in San Antonio, Texas: Dr. Bob Pirok and Dr. Justin Godinho. Dr. Bob Pirok is an Associate Professor at the University of Amsterdam in the Netherlands, where he also completed his Ph.D. under the direction of Professor Peter Schoenmakers. He is an expert in multi-dimensional chromatography and the application of machine learning within the field. At Pittcon we celebrated his receipt of the Emerging Leader in Chromatography Award, presented by LCGC International Magazine. Dr. Justin Godinho is a Senior Principal Scientist at GlaxoSmithKline (GSK) in Upper Providence, Pennsylvania. He completed his undergraduate work at Davidson College and his Ph.D. under the direction of Professor Jim Jorgenson at the University of North Carolina at Chapel Hill. Before joining GSK, he worked in the column manufacturing business with Advanced Materials Technology. He is a recognized expert in column technology at both capillary and analytical scales, as well as the analysis of small and biotherapeutic molecules. At this year's conference, he received the Young Investigator in Separation Science Award, sponsored by the ACS Division of Analytical Chemistry. In the conversation, we discuss the recent award sessions for both guests and the evolution of their respective careers. We explore Justin's transition from fundamental column packing research to biopharmaceutical applications at GSK, touching on the ongoing need for protein-suitable columns, capillary-scale techniques, and the Hydrophobic Subtraction Model column database. We then shift to Bob's research on automated method development discussed at the meeting. This includes a deep dive into data-driven chromatography, the complexities involved in establishing effective Chromatographic Response Functions (CRFs), and why setting realistic expectations for artificial intelligence and automated method development is critical to avoiding a future "AI winter."

On this accredited episode of NP Pulse: The Voice of the Nurse Practitioner®️, join esteemed faculty as they discuss the latest evidence-based guidance, including current recommendations and emerging updates in adult vaccination. The faculty will also be accompanied by two mothers who will share the powerful, impactful experiences of losing their daughters to a vaccine-preventable disease (VPD), meningitis. Upon successful completion of this podcast, you will be able to: Explain the risk and burden of VPDs in adults, including the disproportionate impact among certain subpopulations caused by disparities in patient education and inequitable access. Review the latest Advisory Committee on Immunization Practices (ACIP) adult vaccination recommendations. Identify recent and emerging changes in the adult vaccination landscape. Identify strategies to facilitate the implementation of adult vaccination standards, particularly among vulnerable, minoritized adults and populations at risk for severe disease complications. A participation code will be provided at the END of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center. Click on the "Next Steps" button of the activity and: Enter the participation code that was provided. Complete the activity posttest. Complete the activity evaluation. This will award your CE credit and certificate of completion. 1.0 CE will be available through July 31, 2027. This educational activity is supported by an independent medical education grant from GSK.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/learn/course/recent-research-into-biologics-in-asthma-10830Program DescriptionThis podcast activity provides an in-depth review of several recent trials in severe asthma management, highlighting the ongoing shift in asthma precision medicine towards identifying the right patients for the right treatments. Clinicians will examine clinical data from the NIMBLE trial (depemokimab), alongside the WAYFINDER trial (tezepelumab), as well ZEPHYR 5 (benralizumab), REMOMEPO (mepolizumab), VESTIGE (dupilumab) and VALLIANT (verekitug). This activity will grant clinicians critical insights to move beyond simple exacerbation reduction and precisely align advanced biologic therapies with the underlying cellular biology driving each patient's symptoms.Educational ObjectiveAt the conclusion of this activity, participants should be better able to:Review recent updates in the asthma literature, including recent guideline revisions and evolving clinical trial data for newer biologic therapies.Accredited ProvidersThe National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).FacultyCedric Rutland, BS, MD, FCCPVolunteer FacultyUniversity of CaliforniaPulmonary Critical Care Internal Medicine, ProducerRutland Medical GroupNewport Critical Care PhysiciansLake Forest, CADr. Rutland has disclosed the following financial relationships:Consultant: Sanofi (asthma, diabetes, NP, RSV, AD), Boehringer Ingelheim (IPF, PPF), Regeneron (asthma, diabetes, NP, RSV, AD), Chiesi (asthma), Baxter (bronchiectasis), Insmed (bronchiectasis), AstraZeneca (asthma, cough)Advisor/Advisory Board: Sanofi (asthma, AD, NP), Regeneron (asthma, AD), Chiesi (asthma), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough)Speaker: Sanofi (asthma, NP, AD, AFRS, urticaria, EoE), Regeneron (asthma, NP, AD, AFRS, urticaria, EoE), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough), Chiesi (asthma), Baxter (bronchiectasis)These relationships have ended within last 24 months:Consultant: GSK (asthma, cough, RSV)Advisor/Advisory Board: GSK (asthma, cough, RSV)Speaker: GSK (asthma, cough, RSV)Diego J. Maselli, MD, FCCP, ATSFProfessor and ChiefDivision of Pulmonary Diseases & Critical CareUT Health at San AntonioDirector, Respiratory Care, University Health SystemDirector, Severe Asthma Program, University Health SystemSan Antonio, TXDr. Maselli has disclosed the following financial relationships:Consultant: AstraZeneca (asthma, COPD), Sanofi/Regeneron (asthma, COPD), GSK ( asthma, COPD), Amgen (asthma, COPD), Insmed (bronchiectasis)Speaker: GSK (asthma, COPD), AstraZeneca (asthma, COPD), Amgen (asthma, COPD), Sanofi/Regeneron (asthma, COPD)All of the relevant financial relationships listed for these individuals have been mitigated.Nurse Planner and Peer ReviewerMarjorie Crabtree, DNP, FNP, ANPHaymarket Medical EducationSteering CommitteeNurse Practitioner Healthcare FoundationAccredited Provider Program DirectorBellevue, WADr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.Accredited Provider DisclosureNACE staff has no relevant financial relationships to disclose.Intended AudiencePulmonology, allergy/immunology, and critical care clinicians (physicians, nurse practitioners, and physician associates), as well as primary care and geriatric medicine clinicians caring for patients with asthma.Commercial SupportersThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Welcome back to the Pear Healthcare Playbook! Today we're thrilled to host Ron Alfa, co-founder and CEO of Noetik. Noetik is building an AI-native platform for cancer biology, generating large-scale human data to train biological foundation models that both predict patient responses to therapy and uncover new drug targets and treatment opportunities. Most recently, Noetik signed a $50 million licensing agreement with GSK, giving GSK access to Noetik's virtual cell foundation models, along with one of the largest multimodal spatial oncology datasets assembled to date. In this episode, we discuss Ron's journey to founding Noetik, why building truly useful models of biology requires large-scale, multimodal human data, and how biological foundation models can transform precision oncology. We also explore what it takes to build an AI-native biotech company, lessons from partnering with pharma, the future of drug discovery, and the path toward bringing more personalized cancer treatment to every patient.

On episode #109 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 6/4 – 6/22/26. Host: Daniel Griffin and Sarah Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral CMV viraemia is associated with mortality among children with HIV starting antiretroviral therapy in sub-Saharan Africa (CID) Bacterial Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia(NEJM) A fatal case of Legionella micdadei prosthetic valve endocarditis diagnosed by plasma microbial cell-free DNA metagenomic sequencing (LANCET: Infectious Diseases) Legionnaires Disease Associated with a Private-Use Hot Tub in a Vacation Rental Property — New York, October 2024–April 2025 (CDC: MMWR) Notes from the Field: Case of Legionnaires Disease Associated with a Home Device Used to Mix Powdered Infant Formula — United States, 2025 (CDC:MMWR) Duration of antibiotic therapy for bacteremia in immune compromised hosts—a post hoc subgroup analysis of the BALANCErandomized clinical trial (CMI: Clinical Microbiology and Infection) FDA approves first oral carbapenem therapy for complicated urinary tract infections (FDA) Oral Tebipenem Matched IV antibiotic for complicated UTIs in Phase III Trial (MEDPAGE Today) US FDA approves GSK's oral antibiotic for drug-resistant UTIs (Reuters) Anti–Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a "Hit Hard and Fast" Strategy Improve Outcomes? (CID) Fungal The Last of US Season 2 (YouTube) Oral Wash PCR Improves the Diagnosis of Pneumocystis Pneumonia in Immunocompromised Patients Without HIV: A Prospective Multicenter Study (CID) Miscellaneous Foodborne Disease Outbreaks Associated with Marine Toxins — Foodborne Disease Outbreak Surveillance System, United States, 2011–2023 (CDC: MMWR) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

It hasn't been in many headlines (thanks, AI), but pharmaceutical companies are on a merger & acquisition spree that could break records. With more than $126 billion in deals so far this year, companies are looking for novel drug canddiates and clinical stage companies to bolster their own development pipeline. We'll take a dive into what's driving this M&A frenzy and what companies look interesting in the pharmaceutical space today.Tyler Crowe, Matt Frankel, and Lou Whiteman discuss:- Big Pharma using big wallets for M&A- Who's at risk of running off a patent cliff- Regulatory changes adding fuel to the fire- Companies doing great for patients (and investors)- Mailbag: Is Pfizer ok? Companies discussed: LLY, MRK, UTHR, ASND, PFE, ABBV, GSK, NVO, RHHBYHost: Tyler CroweGuests: Matt Frankel, Lou WhitemanEngineer: Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

He carried two copies of ApoE4, the highest genetic risk factor for Alzheimer's disease, went through medical school knowing exactly what his LDL of 700 meant, decided the experts were wrong, and then published the case report to prove it. In this episode, Louisa sits down with Dr. Nick Norwitz, PhD researcher and metabolic scientist, for one of the most scientifically dense conversations on brain health, cholesterol biology, and Alzheimer's prevention ever recorded on this show. They cover why the phospholipid form of DHA reaches the brain more effectively than standard fish oil, how ApoE4 carriers burn through omega-3s differently and what to do about it, the lithium orotate data that sold out supplement shelves worldwide, and why GSK-3 beta, the enzyme that phosphorylates tau, may be the most under appreciated target in Alzheimer's research today. Then Dr. Nick Norwitz lays out the case that challenges the "LDL is always the enemy" consensus: why metabolically healthy individuals may not benefit from aggressive lipid-lowering therapy, what his viral coronary CT angiogram showed after seven years of 700+ cholesterol, why the EZPAVE trial headlines don't hold up under scrutiny, and what GLP-1s are doing inside the brain completely independent of weight loss. You'll also hear about the sardine diet experiment, the omega-3 thermogenesis connection, ketones as misfolded protein clearance agents, creatine for depression, retatrutide and PCSK9, BPC-157 risks, and what Dr. Nick Norwitz believes is coming in Alzheimer's gene therapy within the next decade. *Reduce your risk of Alzheimer's with my science-backed protocol for women 30+:*https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ *TOPICS DISCUSSED*(00:00:00) Intro: The ApoE4 Paradox and the Case Report That Broke the Internet (00:00:57) Why Standard Omega-3 Supplements Fail and What to Take Instead (00:05:13) DHA and the Phospholipid Carrier: How It Crosses the Blood-Brain Barrier (00:10:19) ApoE4 Explained: Risk, Genetics, and Why Nick Is Optimistic (00:17:38) Why ApoE4 Carriers Burn Through DHA Faster and Need More (00:20:31) Women, Omega-3s, Menopause, and Brain Insulin Resistance (00:21:41) Statins, Sex Differences, and the DHA-Blood Sugar Connection (00:26:01) Statins and Dementia: What the Data Actually Say (00:32:24) Tau, GSK-3 Beta, Lithium Orotate, and Targeting Alzheimer's Pathology (00:42:19) The Glymphatic System, 40Hz Devices, and Sleep as Brain Clearance (00:45:21) Gene Editing, Prime Editing, and the Future of ApoE4 Therapy (00:49:33) Nick's Case Report: 700 LDL, Zero Plaque, and Seven Years of Data (00:55:10) The EZPAVE Trial: Why the Headlines Don't Hold Up (01:00:33) KetoneIQ: Ketones for Brain Energy and Focus (01:01:29) Cheers Health: Supporting Liver Function and Cognitive Recovery (01:03:54) If Not LDL, What Causes Heart Disease in Metabolically Healthy People? (01:12:05) The Oreo Experiment and the Sardine Diet: Self-Experiments in Metabolism (01:19:10) Ketones, Women's Brains, and Clearing Misfolded Proteins (01:21:08) The Full Brain Health Protocol: Omega-3s, Creatine, NAD, Lithium, and More (01:24:01) GLP-1s for the Brain: Independent of Weight, Targeting Amyloid and Tau (01:25:28) Peptides: BPC-157 Risks, Retatrutide, MOTS-c, and What's Worth Watching (01:29:02) Why Nick Is Controversial And Why He Doesn't Mind _______ *Thank you to our sponsors*Fenix Health Science: fenixhealthscience.com Use code NEUROEXPPulsetto: https://pulsetto.tech/pages/NEURO or use Code NEURO for some off your orderFunction Health: https://www.functionhealth.com/louisanicolaBASED Bodyworks: https://basedbodyworks.com/ and use code NEURO for 20% offKetoneIQ: https://ketone.com/NEURO for 30% OFFCheers Health: https://CheersHealth.com/NEURO or use code NEURO for 20% off _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention.If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0Instagram: https://www.instagram.com/louisanicola_/Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices

He carried two copies of ApoE4, the highest genetic risk factor for Alzheimer's disease, went through medical school knowing exactly what his LDL of 700 meant, decided the experts were wrong, and then published the case report to prove it. In this episode, Louisa sits down with Dr. Nick Norwitz, PhD researcher and metabolic scientist, for one of the most scientifically dense conversations on brain health, cholesterol biology, and Alzheimer's prevention ever recorded on this show. They cover why the phospholipid form of DHA reaches the brain more effectively than standard fish oil, how ApoE4 carriers burn through omega-3s differently and what to do about it, the lithium orotate data that sold out supplement shelves worldwide, and why GSK-3 beta, the enzyme that phosphorylates tau, may be the most under appreciated target in Alzheimer's research today. Then Nick lays out the case that challenges the "LDL is always the enemy" consensus: why metabolically healthy individuals may not benefit from aggressive lipid-lowering therapy, what his viral coronary CT angiogram showed after seven years of 700+ cholesterol, why the EZPAVE trial headlines don't hold up under scrutiny, and what GLP-1s are doing inside the brain completely independent of weight loss. You'll also hear about the sardine diet experiment, the omega-3 thermogenesis connection, ketones as misfolded protein clearance agents, creatine for depression, retatrutide and PCSK9, BPC-157 risks, and what Nick believes is coming in Alzheimer's gene therapy within the next decade. Reduce your risk of Alzheimer's with my science-backed protocol for women 30+:https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ TOPICS DISCUSSED 00:00 Intro: The ApoE4 Paradox and the Case Report That Broke the Internet 00:57 Why Standard Omega-3 Supplements Fail and What to Take Instead 05:13 DHA and the Phospholipid Carrier: How It Crosses the Blood-Brain Barrier 10:19 ApoE4 Explained: Risk, Genetics, and Why Nick Is Optimistic 17:38 Why ApoE4 Carriers Burn Through DHA Faster and Need More 20:31 Women, Omega-3s, Menopause, and Brain Insulin Resistance 21:41 Statins, Sex Differences, and the DHA-Blood Sugar Connection 26:01 Statins and Dementia: What the Data Actually Say 32:24 Tau, GSK-3 Beta, Lithium Orotate, and Targeting Alzheimer's Pathology 42:19 The Glymphatic System, 40Hz Devices, and Sleep as Brain Clearance 45:21 Gene Editing, Prime Editing, and the Future of ApoE4 Therapy 49:33 Nick's Case Report: 700 LDL, Zero Plaque, and Seven Years of Data 55:10 The EZPAVE Trial: Why the Headlines Don't Hold Up 01:00:33 KetoneIQ: Ketones for Brain Energy and Focus 01:01:29 Cheers Health: Supporting Liver Function and Cognitive Recovery 01:03:54 If Not LDL, What Causes Heart Disease in Metabolically Healthy People? 01:12:05 The Oreo Experiment and the Sardine Diet: Self-Experiments in Metabolism 01:19:10 Ketones, Women's Brains, and Clearing Misfolded Proteins 01:21:08 The Full Brain Health Protocol: Omega-3s, Creatine, NAD, Lithium, and More 01:24:01 GLP-1s for the Brain: Independent of Weight, Targeting Amyloid and Tau 01:25:28 Peptides: BPC-157 Risks, Retatrutide, MOTS-c, and What's Worth Watching 01:29:02 Why Nick Is Controversial And Why He Doesn't Mind _______ Thank you to our sponsors Fenix Health Science: fenixhealthscience.com Use code NEUROEXP Pulsetto: https://pulsetto.tech/pages/NEURO or use Code NEURO for some off your order Function Health: https://www.functionhealth.com/louisanicola BASED Bodyworks: https://basedbodyworks.com/ and use code NEURO for 20% off KetoneIQ: https://ketone.com/NEURO for 30% OFF Cheers Health: https://CheersHealth.com/NEURO or use code NEURO for 20% off _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices

How do you rebuild a company's entire capability infrastructure — and fund the transformation through the savings it generates? Zaka Farhat is Global SVP for Talent, Learning, Organisation and Capability Development at GSK, where she leads the company's enterprise-wide skills, learning and capability agenda. In this episode, Zaka shares the full story of how GSK rebuilt its capability infrastructure in 18 months - retiring more than 20 legacy systems, building a single skills and learning ecosystem, and funding the transformation through the savings it generated. Join them as David and Zaka discuss:Why GSK's skills transformation began with a commercial question about capability and cost The five conditions for organisational readiness that had to be in place before any platform launched How GSK approached skills taxonomy, job architecture and inference, and what they had to redo along the way What personalised learning looks like at scale, and how skills data is now shaping workforce planning decisions What GSK chose to stop, and why decommissioning is the step most transformations skip How Zaka's team is measuring impact across three KPI layers This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Hosted on Acast. See acast.com/privacy for more information.

Carl Quintanilla and Jim Cramer led off the show with the tech sector bouncing back from Friday's sell-off for a second straight day. Hear what Jim said about the chip sector rebound. The anchors discussed OpenAI confidentially filing for an IPO after last week's Anthropic filing to go public — and SpaceX slated for its Wall Street debut on Friday. Also in focus: SpaceX's CFO on data centers in space, market reaction to Apple unveiling "Siri AI" at WWDC, GSK buys a cancer drug maker in a $10.6 billion deal, Nvidia CEO Jensen Huang makes his presence felt in South Korea — and dances.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How do the world's most forward-thinking organisations use skills intelligence, market intelligence and work intelligence together to stay ahead? In this episode of the Digital HR Leaders podcast, host David Green is joined by Mik Wornoo, co-founder and President of US at TechWolf, to explore how organisations are using three signals together to build a strategic workforce planning strategy that can keep pace with AI, and what that looks like in practice. In this conversation, David and Mik discuss: What skills intelligence, work intelligence and market intelligence each bring to strategic workforce planning, and why all three matter What work intelligence actually means in practice, and how decomposing work into tasks is changing how organisations understand the impact of AI on their workforce How AI is actively reshaping roles right now, and what that means for strategic workforce planning, job architecture and redeployment Real-world case studies from organisations using all three signals to make smarter workforce decisions and align their people strategy with their AI strategy What it actually looks like to get started, and why the barrier to entry is lower than most HR leaders think This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Resources: TechWolf podcast Hosted on Acast. See acast.com/privacy for more information.